Menu UF Health Home Menu
 

Yan Gong, Ph.D.

Yan Gong

Research Associate Professor

Pharmacotherapy and Translational Research

OFFICE: HSC PG-27

EMAIL: gong@cop.ufl.edu

PHONE: 352-273-6297

CV: Link to CV

 

Education

  • Ph.D. in Pharmaceutics, University of Florida
  • M.S. in Statistics, University of Florida
  • M.S. in Pharmaceutics, West China University of Medical Sciences, Chengdu, Sichuan, P.R. CHINA

Biographical Sketch

Yan Gong, Ph.D., is a Research Associate Professor in the Department of Pharmacotherapy and Translational Research at the University of Florida (UF) College of Pharmacy and the UF Center for Pharmacogenomics. Dr. Gong received a Ph.D. in Pharmaceutics in 2004 from Department of Pharmaceutics, College of Pharmacy at UF. She also obtained a Master’s Degree in Statistics in 2003 from UF Department of Statistics. Before joining the UF faculty in 2005, she completed one year of post-doctoral fellowship in Cardiovascular Pharmacogenomics at the UF Center for Pharmacogenomics.

Dr. Gong’s research focuses on cardiovascular drug pharmacogenomics and disease-gene association that may be relevant to pharmacogenomics. The majority of her research centers around hypertension and cardiovascular adverse outcomes. Dr. Gong is an investigator on multiple randomized controlled hypertension clinical trials such as International VErapamil Trandolapril Study (INVEST), Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) and Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR2). Dr. Gong is also interested in pharmacogenomics of serious adverse drug events. She is currently collaborating with local and international investigators on the pharmacogenomics related to osteonecrosis of the jaw. Dr. Gong has more than 70 publications as author and coauthor in many international journals.

Dr. Gong is also involved in teaching multiple graduate level and professional level courses at the University of Florida, College of Pharmacy and College of Medicine. She is the course coordinator for Pharmacogenomics (PHA6449), a required graduate level course and Introduction to Quantitative Methods in Pharmacy (PHA5719), a required course for the second year professional Pharmacy students.

Dr. Gong is serving as an Editorial Board Member to the journal PLOS ONE since 2011. She is member of American Association of Pharmaceutical Scientists, American Society of Clinical Pharmacology and Therapeutics, American Heart Association and International Society of Genetic Epidemiology.

Affiliations

  • American Association of Pharmaceutical Scientists
  • American Society of Clinical Pharmacology and Therapeutics
  • American Heart Association
  • International Society of Genetic Epidemiology

Research Interests

  • Dr. Gong’s research focuses on cardiovascular drug pharmacogenomics and disease-gene association that may be relevant to pharmacogenomics, and the influence of ethnicity on pharmacogenomics.  She specializes in analysis for Pharmacogenomics associations in experimental and observational studies including genome-wide association studies (GWAS).  The majority of her research centers around hypertension and cardiovascular adverse outcomes, with a focus on proteins/genes that are drug targets and receptors and their impact on disease and drug response.  Dr. Gong is the lead statistical geneticist for INternational VERapamil SR-Trandolapril Study (INVEST) and the Genetic Substudy (INVEST-GENEs).  She is also a co-investigator for Pharmacogenetic Evaluation of Antihypertensives Responses (PEAR) and an active member of the NIH Pharmacogenetics Research Network (PGRN).
  • Dr. Gong is also collaborating with investigators in College of Dentistry, College of Medicine and the Malcom Randall VA Medical Center on the Pharmacogenomics related to adverse drug reaction related to bisphosphonates: bisphosphonate-associated osteonecrosis of the jaw (BONJ).

Publications

Gong Y, Beitelshees AL, Cooper-DeHoff RM, Lobmeyer MT, Langaee TY, Wu J, Cresci S, Province MA, Spertus JA, Pepine CJ, Johnson JA. Chromosome 9p21 Haplotypes and Prognosis in White and Black Patients with Coronary Artery Disease. Circ Cardiovasc Genet, 2011 Apr;4(2):169-78. PMID: 21372283.

Katz J*, Gong Y*, Salmasinia D, Hou W, Burkley B, Ferreira P, Casanova O, Langaee TY, Moreb JS. Genetic Polymorphisms and Other Risk Factors Associated with Bisphosphonate Induced Osteonecrosis of the Jaw (BONJ). Int J Oral Maxillofac Surg, 2011 Jun;40(6):605-11. PMID: 21396799 *first authors.

Niu Y*, Gong Y*, Langaee TY, Davis H, Elewa H, Beitelshees AL, Moss JI, Cooper-DeHoff RM, Pepine CJ, Johnson JA. Genetic Variation in the Beta 2 Subunit of the Voltage-Gated Calcium Channel (CACNB2) and Pharmacogenetic Association with Adverse Cardiovascular Outcomes in the International Verapamil SR-Trandolapril Study-Genetic Substudy (INVEST-GENES). Circ Cardiovasc Genet, 2010 Dec 1;3(6):548-55. PMID:21156931 *first authors.

Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ. Tight Blood Pressure Control and Cardiovascular Outcomes among Hypertensive Patients with Diabetes and Coronary Artery Disease. JAMA, 2010 Jul 7;304(1):61-8. PMID: 20606150.

Gong Y, Handberg EM, Cooper-DeHoff RM, Matyas K, Johnson JA, Pepine CJ, for the INVEST investigators. Systolic Blood Pressure and Subjective Well-being in Patients with Coronary Artery Disease. Clin Cardiol, 2009 Nov;32(11):627-32. PMID: 19711440.

Full Publication List via PubMed